NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
来源：TheNewswire发布于 2026-08-31
Toronto, Ontario, August 31, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd. (Nasd...
相关标的：SPRC
本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。